OmniAb, Inc. (OABI) Earnings Call Transcript & Summary

May 9, 2024

NASDAQ US Health Care Life Sciences Tools and Services earnings 32 min

Earnings Call Speaker Segments

Kurt Gustafson

executive
#1

Thanks, operator, and good afternoon to all of you. I'm Kurt Gustafson, serving as Chief Financial Officer at OmniAb, and I appreciate everyone taking the time to participate in our conference call covering first quarter 2024 financial results. Slides have been prepared to go along with what we discuss today, and you can find them in the Investors area of our site, omniab.com. Prior to getting started, I want to alert our audience that remarks delivered on this call will contain forward-looking statements as defined under the federal securities laws; such forward-looking statements carry risks and uncertainties that might lead to actual outcomes differing materially from any results we anticipate; the cautionary language included in today's press release along with our SEC filings serves to qualify these forward-looking statements. It's important to note that this conference call includes time-sensitive information that holds accuracy only as of today's live broadcast date, May 9th, 2024. Other than as mandated by law, OmniAb assumes no responsibility to revise or update any forward-looking statements in order to reflect events or circumstances arising after the date of this call. With me today is Matt Foehr, who serves as President and CEO of OmniAb. On today's call, Matt and I will walk through highlights regarding the company's operations, updates on partners and technology, and our recent financial results, and once our prepared remarks are finished, we'll take questions from the line; so with that, I'll hand things over to Matt.

Matt Foehr

executive
#2

Appreciate that, Kurt. Afternoon, everyone, and thank you for being with us on today's call covering our first quarter. Since we've seen growth across several important business metrics in quarter after quarter, I take pride in what OmniAb has accomplished across the past 18 months, which set us up for a strong quarter and puts both our business and our pipeline in excellent position for a robust 2024. What we delivered over the first three months of this year shows both how our partner base keeps diversifying and how our footprint around the world keeps widening. Everyone at OmniAb stays sharply focused on the strategic plans we've laid out. We're making our proven technologies more visible, and we remain dedicated to pushing innovation forward so we can build lasting value for those with a stake in our company. The possibilities ahead excite us, and we have confidence in what's coming for our technology and our business as they grow and advance in the years to come. Let me give a quick rundown of our business metrics, beginning on slide 5. Q1 2024 closed with 80 active partners. We signed 3 new platform license agreements in the quarter, among them deals with a Boston-based, venture-backed startup that is very well funded, with ImmunoBiochem Corporation, and with the University of Georgia. We remain dedicated to growing our varied partner base further, and as this slide shows, net of attrition our active partner count has almost doubled since 2018. Greater visibility keeps coming to our technology platform, which keeps growing too, and thanks to our recent technology launches plus our plans to keep innovating, we feel we're positioned well to potentially speed up this partner growth. On active programs, we also recorded growth this quarter net of attrition, with that count rising to 327, as slide 6 illustrates. Compared with recent quarters, Q1 brought a somewhat higher degree of program attrition, and all of it sat in the discovery stage, except for a single case I'll get to shortly. Most of that Q1 discovery-stage attrition came from one Asia-based partner realigning its pipeline, and since programs rose on a net basis during the quarter, new program starts from other partners located in the U.S. and Europe clearly offset that on the positive side. We enjoyed some genuinely encouraging active program progression during the quarter, with 3 programs making a successful move from discovery into the preclinical stage. Let me repeat our definition: preclinical stage programs are those our partners confirm are in pre-IND studies with the goal of moving into human trials. Q1 ended with a record 18 programs sitting in preclinical, the highest count we've ever reached at that stage. As slide 6 shows, we also had 1 program move from the phase I category into phase II, based on what our partner disclosed. Now on to slide 7. As we often point out, losing programs is simply a normal aspect of what we do, and of drug discovery and development in general; during 2023, none of our clinical stage programs were discontinued, yet in Q1, one program at Roche was discontinued, and you can see that on the slide here. Roche halted a phase I program as part of what they described as a wider internal portfolio shaping effort on their part, which they have talked about publicly with a fair amount of detail. They also stated that this choice had nothing to do with safety, efficacy, or the quality of the program, and I would note that this program fell under a legacy fully paid license, so there is zero effect on any future milestones or royalties owed to OmniAb. From what our partners have told us, we still anticipate four to six new entries into clinical development during this year for novel antibody-based programs derived from OmniAb. Now on slide eight, I will discuss selected partner updates along with certain catalysts coming up this year. Immunovant said that worldwide phase 3 clinical trials of batoclimab in myasthenia gravis and thyroid eye disease are moving forward, and that they are still on track for top-line data readout in the second half of 2024 for myasthenia gravis, and in the first half of 2025 for thyroid eye disease. They also anticipate initial Period One data from the phase IIb clinical trial of batoclimab in chronic inflammatory demyelinating polyneuropathy, or CIDP, during the second or third quarter of this year. HanAll Biopharma, working alongside Immunovant, is already conducting a phase III study of batoclimab in generalized myasthenia gravis in Japan, and said that a clinical trial notification was approved so they can begin a phase III study in thyroid eye disease in Japan. Turning to IMVT-1402, Immunovant announced plans to launch four to five potentially registrational programs for IMVT-1402 over their next fiscal year, and also intends to start trials in 10 indications for IMVT-1402 across their next two fiscal years. At the recent AACR conference, Merck shared preclinical data for M9140, a novel ADC with a topoisomerase 1 inhibitor payload that targets CEACAM5 expressing tumors. M9140 showed high potency, strong antitumor activity, and bystander effect in vitro and in mouse models. A first-in-human phase I study evaluating safety, tolerability, PK, and preliminary clinical efficacy in patients with advanced solid tumors is currently underway. Finally, Genmab disclosed that they expect to announce acasunlimab phase II data in second-line non-small cell lung cancer during the first half of the year, and data are now expected at ASCO; and we, like many others focused on the oncology space, are very much looking forward to that update and data. Genmab has also already disclosed plans to initiate a global phase III study of acasunlimab in second-line non-small cell lung cancer later this year. The ASCO Clinical Meeting begins at the end of the month, and will run through June 4th. On slide 9, you'll find a sampling of the talks our partners have lined up covering fresh clinical data from programs derived from OmniAb. I'm also aware this particular slide leaves out a number of partner presentations happening at ASCO, though what we've done is include the ones we believe deserve the most attention from you. Turning to my final slide, number 10, I want to call out several scientific presentations coming soon from members of our team. Our aim is to build stronger visibility around our differentiated technology platform, shining a light on innovations and new workflow improvements that drive benefit for the business and generate value for stakeholders. Thanks to a broader business development footprint, our involvement in scientific conferences is greater today than it has ever been. In the coming week, we'll be in Boston for the PEGS, Protein and Antibody Engineering Summit, where Bob Chen is set to share fresh data on approaches that enable fast and efficient discovery of bispecific antibodies, drawing on the biological intelligence found in our engineered transgenic animals, the deep screening strengths of our xPloration platform, and the machine learning plus AI within our OmniDeep offering. You'll also notice here additional conferences and presentations on our schedule over roughly the next 8 weeks, taking place at the Antibody Engineering and Therapeutics Conference in London and the World ADC Asia Conference in South Korea.

Matt Foehr

executive
#3

I'd like to bring up a recent peer-reviewed paper from our researchers that deals with VHH antibodies derived from chickens, which appeared in the Journal of Immunology. It was published online quite recently, and it gives more exposure to our OmnidAb technology, which we introduced during Q4 of last year. OmnidAb is drawing in additional partners, creating fresh market possibilities for us, and right now it's being used by a number of partners in industry and academia. Before passing the call back to Kurt, I'd like to note that having successfully set up OmniAb as an independent company, and with a favorable growth trajectory, we're still positioned to meet our objectives and to capitalize on the efficiencies from what we previously invested in the business. As an organization, we're dedicated to tackling the toughest problems in antibody-based drug discovery, and we intend to keep improving our technology offerings — something we're eager to pursue through our streamlined, highly scalable business model. With that said, I'll hand things back to Kurt so he can discuss our first quarter financial results. Kurt? Thanks, Matt. I've only got a few slides covering our financials, so beginning on slide 12, there's a summary of how we performed financially during the first quarter of 2024. Total revenue came in at $3.8 million for the first quarter, versus $16.9 million during the same period a year earlier. That decline was mainly attributable to recognizing the $10 million TECVAYLI EU launch milestone, which had been recorded in the first quarter of 2023. Service revenue declined, largely because we finished our discovery work on specific ion channel programs. First quarter revenue matched what we had anticipated, and you may remember that during our Q4 earnings call, I mentioned we were expecting milestone payments to be weighted toward the second half of the year, based on what partners told us in their public statements. That remains our expectation. Now for operating expense: our R&D expense during the first quarter reached $14.6 million, up from $13.8 million in the prior quarter, with the rise mainly driven by greater personnel costs. Where G&A is concerned, expenses were comparable to last year, landing at $8.3 million. Our operating expenses are likewise coming in as we expected, and we continue to anticipate that operating expenses for 2024 will be roughly equal to those in 2023, since we're now fully staffed and resourced to take advantage of the business's future growth. One more point regarding the tax rate. Looking ahead, our deferred tax liabilities are no longer anticipated to fully offset our deferred tax assets in future periods, so we needed to set up a valuation allowance, which drove our effective tax rate down; broadly speaking, we now anticipate our effective tax rate will land in the low to mid-teens moving forward, though it may vary from quarter to quarter depending on when certain discrete items occur. For the first quarter, our net loss came to $19 million, which works out to $0.19 per share. That compares with a net loss of $6.1 million, or $0.06 per share, during the same period a year earlier. If you turn to slide 13, you'll see we closed the first quarter of 2024 with $69 million in cash. During our Q4 earnings call, we told you Q1 would represent our biggest burn quarter of this year, driven by the timing of milestones along with certain compensation cycle items, and that's exactly how things unfolded. Looking at the full year, we're reaffirming our guidance that cash use will be fairly comparable to what we used in 2023, once you set aside the $35 million TECVAYLI milestone we received last year. We also continue to believe our cash balance plus cash generated from operations ought to give us enough capital to fund operations for the foreseeable future. With that said, I'd like to open things up for questions. Operator?

Executive

executive
#4

Hey everyone, good evening. Julianne here, filling in for Steve. Thanks for taking my question, and congratulations on the progress. Before I go on, can you all hear me fine?

Kurt Gustafson

executive
#5

Yes, we can hear you.

Executive

executive
#6

Alright, fantastic, and congratulations on the headway. Now, since there are several distinct programs sitting at different phases, correct? So would you mind adding a remark regarding what share of those programs actually carry downstream royalty involvement? That's my first question. And my second question — Matt also brought up the possibility of 4 to 6 fresh programs going into the clinic during this year. Is there anything... for instance, what share of those programs belong to which particular platform? If you're able, could you give some extra detail on that, please? Thanks.

Matt Foehr

executive
#7

Okay, thank you. I might offer a few remarks, and then Kurt can add anything I overlook. When it comes to programs with downstream economics: out of the 327 active programs that our partners are actively investing in and moving through discovery and development, only a very small share — roughly 2% — lack downstream economics and participation for OmniAb. That roughly 2% of the 327 are legacy licenses, old licenses we inherited, in which partners basically held a fully paid license to a predecessor company that we acquired. So I think that probably gives you the color you need there. As for the four to six new programs entering clinical trials this year, we're actually excited about those. Some are getting very close to the clinic; we expect a couple of those to be OmniChicken-derived, one with a large multinational player, and the others will likely be a mix of our source technologies, our other source technologies. So hopefully that helps you.

Executive

executive
#8

Yes, thank you very much.

Matt Foehr

executive
#9

Thank you.

Nishant Gandhi

analyst
#10

Hi everyone, Nishant here. I appreciate you answering our questions. I'm asking on behalf of Kripa. I realize you don't disclose deal terms for particular partnerships, but just to get an idea of how much these deal terms differ — for instance, you signed an agreement with the University of Georgia and also one with a startup robotics firm — so economically speaking, how do these arrangements differ? Any detail you could give would be terrific. Then I have a follow-up.

Kurt Gustafson

executive
#11

Yes, so I'd say regarding how the majority of deals begin, they all essentially begin from an identical term sheet and then get negotiated from that point. Consequently, every term winds up somewhat distinct, yet they stay within a comparable range, and we've given some guidance previously regarding those, what they look like. I will say, however, that often arrangements involving academic institutions get structured a bit differently, since generally speaking, those institutions won't take something all the way through clinical development and launch it. Thus with these arrangements, the manner in which the economics are mainly structured is that we'd get a percentage of whatever they ultimately receive when they either sell the asset or license it out; and often that percentage might shift based on how far they took the asset, correct? Should they license it out during preclinical versus phase I versus phase II, that percentage can occasionally shift; so I'd say for our — for commercial companies, there's some variation, though it isn't enormously different. And regarding academic institutions, the fundamental structure of the arrangement is somewhat different; so I don't know, Matt, whether you have anything to add regarding that one.

Matt Foehr

executive
#12

No, I think you covered it well. Thanks.

Kurt Gustafson

executive
#13

All right.

Nishant Gandhi

analyst
#14

Great. So regarding curiosity from outside collaborators, could you give us some detail on which platforms have drawn more attention over the last quarter, and in particular the recently introduced OmnidAb? Thanks.

Matt Foehr

executive
#15

Yes, Nishant, that's a wonderful question; we, you know, thanks to our, I'd call it, clear sense of purpose and dedication to ongoing innovation, combined with how much validation our platforms have received, the volume of inbound interest from partners reaching out to us has never been higher; we've likewise grown our share of voice and scaled up our business development team across the world; so I believe that too is adding to the growing interest in the platform. Since we revealed the OmnidAb launch at the AAT conference, late last year, it has gone quite well when it comes to utilizing and rolling out a new technology. As I mentioned during prepared remarks, we now have several industry partners along with academic partners using the platform. We're genuinely very enthusiastic about it for numerous reasons. First, it creates fresh opportunities and fresh markets for us. As for our partners, what draws them is the character of domain antibodies and what that delivers when it comes to unlocking alternative routes of administration, improved penetration, rapid tunable clearance, crossing the blood-brain barrier, things of that nature. So that's pulling in plenty of interest from new partners as well as ones we already had. And beyond that, it's unlocking possibilities in new markets, such as imaging and diagnostics and theranostics and similar areas; so, yes, we're thrilled about it, and I believe this is an excellent moment for new technologies. Such conversations keep shaping the way we innovate for the future too.

Nishant Gandhi

analyst
#16

Excellent, I appreciate you answering my questions, and congratulations on the advancement.

Kurt Gustafson

executive
#17

Thank you, Nishant.

Jack Siedow

analyst
#18

Hey everyone, Jack here filling in for Matt. During the past twelve months, it appeared as though competitors across our sector were having a hard time securing new deals, simply because conditions were so tough, yet your company wasn't. Could you give us some insight into what you're picking up from... Thank you.

Matt Foehr

executive
#19

Sure. Appreciate that, Jack. Sounds like maybe your line dropped out near the end there, however, what I'd say is, well, the... indeed, over the past two years, this has clearly been widely reported, 2022 and 2023 stood as stretches when raising capital proved tough for numerous biotech firms, when, I'd say collaborators, whether big or small, were being more careful with pipeline budgets, cutting back on programs, and similar moves throughout the sector; even so, when you examine our numbers, entirely excluding attrition, we managed to deliver quite impressive expansion regarding fresh programs and fresh collaborators. That genuinely reflects the technology we bring to collaborators, our sharpness of mission and our approach, when it comes to, of working alongside them. And during such stretches, similar to the previous two years, I believe collaborators truly seek out proven technologies along with reliable and seasoned partners, plus those dedicated to innovation and addressing their requirements, for partnering. So I'd argue that accounts for much of it. I'd also attribute a great deal to our staff, who genuinely possess a partner-centric approach in how we engage with our collaborators, and I believe that's fueling it too. So currently, with, you know, as last year wrapped up and this year began, with, additional investment flowing toward biotech, I believe this could generate, favorable momentum for the sector, overall; still, we feel truly excellent regarding the operation we're managing and the technology we provide to collaborators.

Jack Siedow

analyst
#20

That's useful. I'll get back in line. Thank you.

Kurt Gustafson

executive
#21

Thank you.

Michael Sonntag

analyst
#22

Hey there, good afternoon to all of you. So, yeah, I'm covering for Puneet — Michael here. For my first question, I suppose it's somewhat connected to... I think you brought up that within your discovery pipeline, a single partner based in Asia is having work cancelled, which is being balanced out by the U.S. and Europe. So I was somewhat interested in whether you could offer any view on, I suppose, how healthy the different biotech sectors are by region and, I suppose, how much exposure you have to a few of those regions?

Matt Foehr

executive
#23

Yes, Michael, thank you. As I noted during prepared remarks, what we observed during Q1 — and genuinely regard as, more or less, a one-time bump in attrition — was tied to one partner located in Asia that was reordering its pipeline and cutting back on discovery assets. That said, I'd point out that new program launches have begun at a really strong pace. Our reported figures are net of attrition; this strikes us as, more or less, a situation involving just one partner. I wouldn't attribute anything here to wider geographic trends or anything of that sort. Clearly, we've grown our business development group at this point, and we keep working on new contracts while bringing on additional partners, just as happened during Q1. Kurt, is there anything you feel like adding?

Kurt Gustafson

executive
#24

Not really — from a regional perspective, I can't point to anything specific that stands out. As you put it, Matt, ultimately what we're betting on is that breakthrough tech comes out on top, and up to this point, that seems to be what's happening.

Michael Sonntag

analyst
#25

All right, excellent. And then there was something else I wanted to ask about, I suppose, in connection with the BIOSECURE legislation that has been put forward in Congress. From what I understand, WuXi is among the partners providing OmniRat as a service. I was wondering whether you've formed any initial views about what could happen to the business if BIOSECURE gets passed?

Matt Foehr

executive
#26

Yes, Michael. So, yes, WuXi, and let me be precise. WuXi — that was WuXi Biologics. OmniRat was adopted by them at a very early stage, and in fact just OmniRat, through a legacy arrangement with a predecessor company that we bought, correct? So, in my view, they have quite a small number of even active programs running over time; however, the legislation currently under debate in Congress isn't anticipated to produce any meaningful or direct effect on our operations. You know, that being said, clearly, it has received a great deal of attention, simply because of the position WuXi occupies within the broader biotech ecosystem, yet we don't anticipate it affecting any programs that we regard as value drivers, nor do we really anticipate it producing any meaningful effect on our business whatsoever.

Michael Sonntag

analyst
#27

Great. Thank you very much.

Kurt Gustafson

executive
#28

Thanks, Michael.

Jacqueline Kisa

analyst
#29

Hello, I'm Jacqueline Kay Kisa, filling in for Steven Mah. I really appreciate you taking my questions. Regarding those new licenses, could you share additional detail about the therapeutic focus or the anticipated program size from these organizations? Also, how does the split look when it comes to platform usage, and do you expect that to change as OmnidAb keeps building momentum?

Matt Foehr

executive
#30

Yes, Jacqueline, I appreciate the question. So, when it comes to the partners we brought on during Q1, ImmunoBiochem is a genuinely intriguing organization; they came out of the Johnson & Johnson JLABS incubator, and their headquarters are located in Toronto. Their work centers on oncology and immuno-oncology, particularly within the micro tumor environment; therefore, I believe our technologies align quite well with what they're pursuing. And clearly, we will be supporting them and already are. The University of Georgia, via their Innovation Gateway Incubator, is another new partner, and that arrangement follows a revenue share structure, just as Kurt described. They also possess a truly fascinating background, not just when it comes to innovation and infectious diseases, but in oncology too. So that, you know, is a partner we're thrilled to now have working with us and to be collaborating alongside. Then, regarding the final partner, there isn't much I'm able to share about them. They are a stealth venture-backed startup located in Boston that is very well-funded. From our standpoint, I suppose I can mention that they're a proven team who understand both our technology and our people well, though that's likely everything I can disclose right now. My expectation is that they will speak more openly down the road.

Jacqueline Kisa

analyst
#31

Excellent, thank you, I appreciate that. Now, is there anything new regarding OmniDeep—updates or launches—that we might not have heard about, or that we can anticipate over the next few quarters? Also, has interest in the platform picked up, and what has the feedback from users been like?

Matt Foehr

executive
#32

Yeah, no, that's a great question, Jacqueline. For the near term, I'd point you toward next week's presentation at PEGS. Bob Chen will be sharing data focused on truly bringing together the biological intelligence of our transgenic animals plus our high-throughput single B-cell screening technology and capabilities with xPloration and our OmniDeep platform. And truly, OmniDeep is a suite of in silico AI and machine learning tools that run throughout our technology stack. What our partners value about it is really the capacity to combine it with high-quality input data from our transgenic animals and the hits that xPloration can produce. Marrying that with variational encoder, or VAE, deep learning models we've created in order to propose new hits, and then additionally using in silico developability filters and similar things; so we're using OmniDeep as a component of what we offer our partners, a number of large pharma partners who are using it, plus collaborations with academics and others. So the — ever since we launched OmniDeep as a brand last May, so almost precisely 1 year ago, the response to it has been very strong as well. Clearly we've been in this space for quite a while, leaning into AI and machine learning alongside our other technologies for many years.

Jacqueline Kisa

analyst
#33

Excellent, thanks. I'm grateful for these questions.

Kurt Gustafson

executive
#34

Thanks to you.

Matt Foehr

executive
#35

Alright, thanks everyone for being here on today's call. We're eager to keep all of you posted as this year moves along and as the business moves along. Over the next few months, we'll be on the road fairly often at quite a few conferences, and we're looking forward to bringing you updates. Thanks once more for tuning in, and enjoy the rest of your day.

Operator

operator
#36

Everyone, that brings today's call to a close. We appreciate your joining us, and we'd ask that you kindly hang up your phones now.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete OmniAb, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to OmniAb, Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in OmniAb, Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.